Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Giovanni Piza Rodriguez"'
Autor:
Christine Chen, Esther Masih-Khan, Manjula Maganti, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Donna E. Reece, Henry Chan, Sophia Farooki, Anca Prica, Madeline Phillips, Giovanni Piza Rodriguez
Publikováno v:
Clinical lymphoma, myelomaleukemia. 18(3)
Background Translocation t(4;14) has traditionally been classified as a high-risk cytogenetic feature in patients with multiple myeloma with shortened progression-free (PFS) and overall survival (OS) despite initial response to treatment. Recent data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::65039d1b477931a68686debd8d19b6f6
https://pubmed.ncbi.nlm.nih.gov/29397346
https://pubmed.ncbi.nlm.nih.gov/29397346
Autor:
Martha L Louzada, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Julie Stakiw, Anca Prica, Darrell White, Kevin W. Song, Michael Sebag, Christine Chen, Donna E. Reece, Harminder Paul, Giovanni Piza Rodriguez, Terrance Comeau, Christopher P. Venner, Mariela Pantoja, Jean Roy, Arleigh McCurdy
Publikováno v:
Blood. 134:4570-4570
Although melphalan 200 mg/m2 (Mel 200) followed by ASCT has been a standard approach for eligible multiple myeloma (MM) patients (pts) for over 25 years, efforts to improve transplant results continue, particularly in high-risk (HR) pts. One approach
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61475e4106f8bf95abed09d83296460b
https://doi.org/10.1182/blood-2019-129357
https://doi.org/10.1182/blood-2019-129357
Autor:
Mariela Pantoja, A. Keith Stewart, Vishal Kukreti, C. Chen, Giovanni Piza Rodriguez, Suzanne Trudel, Donna E. Reece, Wei Xu, Joseph R. Mikhael
Publikováno v:
Journal of Clinical Oncology. 26:4777-4783
Purpose The combination of oral weekly cyclophosphamide and alternate day prednisone is a convenient regimen for relapsed/refractory multiple myeloma (MM), and we sought to improve its efficacy by adding bortezomib, a proteasome inhibitor with proven
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9004967e6789b0632278515b73665e5
https://doi.org/10.1200/jco.2007.14.2372
https://doi.org/10.1200/jco.2007.14.2372
Autor:
Chritopher Venner, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Harminder Paul, Donna E. Reece, Giovanni Piza Rodriguez, Mariela Pantoja, Leonard Minuk, Jean Roy, Kevin W. Song, Christine Chen, Anca Prica, Michael Sebag, Jason Tay, Terrance Comeau, Julie Stakiw, Darell White
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 15:e51-e52
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a680d406ea548bd57631b4856d1bd3f2
https://doi.org/10.1016/j.clml.2015.07.190
https://doi.org/10.1016/j.clml.2015.07.190
Autor:
Martha L Louzada, Michael Sebag, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Mariela Pantoja, Kevin W. Song, Harminder Paul, Christine Chen, Julie Stakiw, Arleigh McCurdy, Terrance Comeau, Christopher P. Venner, Anca Prica, Giovanni Piza Rodriguez, Jean Roy, Donna E. Reece, Darrell White
Publikováno v:
Blood. 128:4632-4632
MRD negativity has become an important goal of the initial treatment of MM pts. Our phase 2 multi-center clinical trial, conducted in 10 major Canadian transplant centers, was designed to increase the MRD negativity rate after ASCT by using condition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82e5fce0e3df7bfc3ffd1e490054504a
https://doi.org/10.1182/blood.v128.22.4632.4632
https://doi.org/10.1182/blood.v128.22.4632.4632
Autor:
Michael Sebag, Christopher P. Venner, Kevin W. Song, Christine Chen, Giovanni Piza Rodriguez, Prica Anca, Leonard Minuk, Jean Roy, Suzanne Trudel, Rodger E. Tiedemann, Mariela Pantoja, Vishal Kukreti, Donna E. Reece, Harminder Paul, Darrell White, Julie Stakiw, Jason Tay, Terrance Comeau
Publikováno v:
Blood. 126:1982-1982
As therapy for MM improves, methods more sensitive than conventional serum/urine electrophoresis/immunofixation are required to optimally evaluate response. Our phase 2 multi-center clinical trial, conducted in 10 Canadian centers, utilized serial bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f2e38b276ab1b6d9d8558188e1d87a2c
https://doi.org/10.1182/blood.v126.23.1982.1982
https://doi.org/10.1182/blood.v126.23.1982.1982
Autor:
Michael Sebag, Kevin W. Song, Christine Chen, Anca Prica, Christopher P. Venner, Julie Stakiw, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Terrance Comeau, Donna E. Reece, Jason Tay, Mariela Pantoja, Giovanni Piza Rodriguez, Leonard Minuk, Jean Roy, Darrell White
Publikováno v:
Blood. 124:3990-3990
Conventional immunoglobulin (Ig) markers have been used to define multiple myeloma (MM) responses, but assessment of marrow for minimal residual disease (MRD) may provide better information on disease status/prognosis (Paiva B, et al. Blood 2008; 112
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e981950ed87382b2e5d1a5029f8ba9ff
https://doi.org/10.1182/blood.v124.21.3990.3990
https://doi.org/10.1182/blood.v124.21.3990.3990
Autor:
Young Trieu, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Donna E. Reece, Christine Chen, Giovanni Piza Rodriguez, Esther Masih-Khan
Publikováno v:
Journal of Clinical Oncology. 32:e19568-e19568
e19568 Background: We previously defined the efficacy of CyBor-P, a 28-day regimen consisting of cyclophosphamide 300 mg/m2 (days 1,8,15, 22), bortezomib 1.5 mg/m2 (days 1,8, 15) and prednisone 100...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1840259ed0d21a637133cbf9e46c0e74
https://doi.org/10.1200/jco.2014.32.15_suppl.e19568
https://doi.org/10.1200/jco.2014.32.15_suppl.e19568
Autor:
Mariela Pantoja, Nizar J. Bahlis, Andrew Belch, Giovanni Piza Rodriguez, Donna E. Reece, Gayle Jenkins, Christine Chen, David Szwajcer, Leonard Minuk, Lisa W. Le, Darrell White, Chaim Shustik, Suzanne Trudel, Rodger E. Tiedemann, Vishal Kukreti, Michael Sebag, Julie Stakiw
Publikováno v:
Blood. 118:3982-3982
Abstract 3982 Newly diagnosed multiple myeloma (MM) patients (pts) with t(4;14) identified by FISH who undergo a single ASCT after older induction regimens have a median progression-free survival (PFS) of only 8–9 months (mos) and median overall su
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb67af6925933a4a4d42b8990437f55a
https://doi.org/10.1182/blood.v118.21.3982.3982
https://doi.org/10.1182/blood.v118.21.3982.3982
Autor:
Michael J. Kovacs, David Szwajcer, Giovanni Piza Rodriguez, Andrew R. Belch, Peter Anglin, Chaim Shustik, Nizar J. Bahlis, Darrell White, Mariela Pantoja, Christine Chen, Suzanne Trudel, Vishal Kukreti, Donna E. Reece
Publikováno v:
Blood. 116:1968-1968
Abstract 1968 Two previous studies have reported that multiple myeloma (MM) patients (pts) with t(4;14), identified by FISH cytogenetics, experience a median progression-free survival (PFS) of only 8–9 mos and median overall survival (OS) of 18 mos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b37be1365385f4f71bd5d76a8567bdb9
https://doi.org/10.1182/blood.v116.21.1968.1968
https://doi.org/10.1182/blood.v116.21.1968.1968